Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Editas Medicine, Inc. (NASDAQ: EDIT).

Full DD Report for EDIT

You must become a subscriber to view this report.


Recent News from (NASDAQ: EDIT)

Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12
Key events next week - healthcare
Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 12:02
Next-generation CRISPR gene editing technology on the way
ScienceDaily reports that researchers at the Joint Institute of Metrology and Biology, a collaboration between Stanford University and the National Institute of Standards and Technology,  have developed a new CRISPR platform called MAGESTIC ("multiplexed accurate genome editing with s...
Source: SeekingAlpha
Date: May, 11 2018 09:44
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ...
Source: SeekingAlpha
Date: May, 09 2018 05:37
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:0...
Source: GlobeNewswire
Date: May, 08 2018 08:00
My Favorite Investment For The Coming Biotech Bull Market (Avisol Capital Partners)
Avisol Capital Partners is a leading contributor on Seeking Alpha and one of three Seeking Alpha contributors participating in the May 2018 Biotech Summit. In his interview, I spoke with Dr. Udaya Maiya from the Avisol team. During our discussion, I asked him about his thoughts on the cu...
Source: SeekingAlpha
Date: May, 07 2018 11:08
Editas up 6% after Q1 update, expanded collaboration with Celgene
Editas Medicine ( EDIT +5.6% ) is on below-average volume on the heels of its Q1 report after the close yesterday. More news on: Editas Medicine, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 04 2018 12:10
Editas Medicine's (EDIT) CEO Katrine Bosley on Q1 2018 Results - Earnings Call Transcript
Editas Medicine (EDIT) Q1 2018 Earnings Conference Call May 03, 2018 05:00 PM ET Executives Mark Mullikin - IR Katrine Bosley - CEO Charlie Albright - CSO Vic Myer - CTO Andrew Hack - CFO Analysts Cory Kasimov - JPMorgan Vikram Purohit - Morgan Stanley Peter Lawson ...
Source: SeekingAlpha
Date: May, 03 2018 20:52
Editas Medicine beats by $0.15, misses on revenue
Editas Medicine (NASDAQ: EDIT ): Q1 EPS of -$0.67 beats by $0.15 . More news on: Editas Medicine, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 16:09

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1329.7029.3630.0829.01670,062
2018-08-1028.5029.6429.8828.50618,271
2018-08-0927.7028.6630.6027.631,584,381
2018-08-0828.7227.6528.7227.59734,697
2018-08-0728.0128.8329.0026.001,897,700

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-13102,656165,45162.0462Short
2018-08-1072,999154,28447.3147Short
2018-08-09212,157405,16552.3631Short
2018-08-0869,381191,88436.1578Short
2018-08-07273,205539,91850.6012Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EDIT.


About Editas Medicine, Inc. (NASDAQ: EDIT)

Logo for Editas Medicine, Inc. (NASDAQ: EDIT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,708,484,189 - 05/15/2018
  • Issue and Outstanding: 46,884,857 - 02/28/2018

 


Recent Filings from (NASDAQ: EDIT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 16 2018

 

 


Daily Technical Chart for (NASDAQ: EDIT)

Daily Technical Chart for (NASDAQ: EDIT)


Stay tuned for daily updates and more on (NASDAQ: EDIT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EDIT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EDIT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EDIT and does not buy, sell, or trade any shares of EDIT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/